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Abstract 
Background: The immunomodulation of the antitumor response driven by immunocheckpoint inhibitors (ICIs) such 
as PD-L1 (Programmed Death Ligand-1) monoclonal antibody (α-PD-L1) have shown relevant clinical outcomes in 
a subset of patients. This fact has led to the search for rational combinations with other therapeutic agents such as 
Doxorubicin (Dox), which cytotoxicity involves an immune activation that may enhance ICI response. Therefore, this 
study aims to evaluate the combination of chemotherapy and ICI by developing Dox Immunoliposomes functional-
ized with monovalent-variable fragments (Fab’) of α-PD-L1.
Results: Immunoliposomes were assayed in vitro and in vivo in a B16 OVA melanoma murine cell line over-express-
ing PD-L1. Here, immune system activation in tumor, spleen and lymph nodes, together with the antitumor efficacy 
were evaluated. Results showed that immunoliposomes bound specifically to PD-L1+ cells, yielding higher cell 
interaction and Dox internalization, and decreasing up to 30-fold the  IC50, compared to conventional liposomes. This 
mechanism supported a higher in vivo response. Indeed, immunoliposomes promoted full tumor regression in 20% 
of mice and increased in 1 month the survival rate. This formulation was the only treatment able to induce significant 
(p < 0.01) increase of activated tumor specific cytotoxic T lymphocytes at the tumor site.
Conclusion: PD-L1 targeted liposomes encapsulating Dox have proved to be a rational combination able to 
enhance the modulation of the immune system by blocking PD-L1 and selectively internalizing Dox, thus successfully 
providing a dual activity offered by both, chemo and immune therapeutic strategies.
Keywords: Liposome, PD-L1, Doxorubicin, Chemo-immunotherapy, Immunotherapy, Immunogenic cell death, 
Melanoma, Immunocheckpoint
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 
zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The immune system is able to detect and eliminate the 
majority of tumors at early stages of development [1]. 
However, cancer cells can evade this process by modu-
lating certain mechanisms such as the up-regulation of 
immune checkpoints.
Programmed Death-ligand-1 (PD-L1) [2–5] is an 
immune checkpoint commonly over-expressed in tumor 
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cells that binds to the Programmed Death-1 (PD-1) 
receptor, present on activated effector T cells [3, 6, 7]. At 
the tumor microenvironment, the interaction of PD-1/
PD-L1 induces the down-regulation of T cell antitumor 
activity and the secretion of inhibitory cytokines, causing 
immunosuppression and promoting tumor progression 
[3, 7].
In recent years, blockade of the PD-1/PD-L1 axis using 
specific monoclonal antibodies has become a promising 
approach in oncology [2–5]. These immune checkpoint 
inhibitors (ICIs) have shown relevant clinical outcomes 
[2, 3, 8–12]. However, the high inter-individual variabil-
ity observed with these treatments has led to the search 
for rational combinations with other strategies such as 
chemotherapeutic agents, to increase the benefit of the 
immunotherapy [7, 13, 14].
In this context, Doxorubicin (Dox) is a good candi-
date for combination with ICIs. Dox induces cytotox-
icity, releasing tumor antigens, which may contribute 
efficiently to stimulate the immune system by the immu-
nogenic tumor cell death mechanism that participates 
promoting the infiltration of effector  CD8+ T cells, 
responsible for the antitumor effect [15–18].
Currently, Dox is administered into liposomal formu-
lations to reduce certain life-threatening side effects, 
in particular cardiotoxicity [18–20]. Furthermore, 
liposomes tend to passively accumulate in tumor tissue 
by the Enhanced Permeability and Retention effect, a 
mechanism driven by the rapid tumor growth that gen-
erates immature leaky new blood vessels that allows an 
increased exposure to the drug in the tumor site [21–23].
On the other hand, immunoliposomes or liposomes 
decorated at the surface with whole monoclonal anti-
bodies or variable monovalent fragments (Fab’), promote 
active targeting [24] by a selective binding to the target, 
which must be upregulated in cancer cells. This mecha-
nism increases intracellular drug bioavailability [25] and 
thereby, improves antitumor drug efficacy [24–26].
Accordingly, PD-L1, commonly over-expressed in 
many solid cancers and often involved in  CD8+ T cell 
exhaustion, represents an attractive target for immu-
noliposomes [27–29]. In fact, our group has developed 
empty PD-L1 targeted liposomes that have demonstrated 
selective binding and a timid immune modulation of 
effector T cells in a melanoma murine model [30]. How-
ever, in this study the aim is to evaluate the advantages 
derived from the combination of chemo-and immuno-
therapy developing Dox-liposomes functionalized with 
Fab’ of α-PD-L1. Our hypothesis states that immunoli-
posomes may induce the reversion of the immunosup-
pressive tumor microenvironment by blocking the PD-1/
PD-L1 interaction and contributing to increase cell inter-
nalization of Dox and thereby, drug cytotoxicity and 
immunogenic cell death activity, a dual mechanism able 
to promote an enhancement of the antitumor response.
Results
Immunoliposomes yielded a reproducible and stable 
nanoplatform
The film-hydration method provided homogenous lipo-
somal populations, as is listed in Table  1. Indeed, the 
three formulations, conventional empty liposomes (LP), 
conventional or non-targeted Dox liposomes (LPD) and 
Fab’-anti-PD-L1 Dox liposomes or targeted liposomes 
(LPF) (Additional file 1: Table S1), showed similar phys-
icochemical characteristics, demonstrating that the 
encapsulation of Dox or the conjugation of Fab’ did not 
influence the parameters.
The efficiency of encapsulation was ≥ 90 ± 3.8% in all 
cases, while the efficiency of antibody conjugation was 
37.9 ± 6.02%.
Accumulative drug release curves in Fig.  1 show that 
Dox released during 1  h from both formulations, LPD 
and LPF, was very low (< 10%), supporting an adequate 
stability for in vivo administration. In addition, the long-
term stability of formulations in Hepes saline (pH 6.7) at 
4 °C was evaluated for 3 months. Results for particle size, 
Table 1 Physicochemical characterization of the different 
liposomal formulations. Data represent the mean ± SD of three 
independent batches
PDI: Polydispersity index; LP: conventional empty liposomes; LPD: conventional 
Dox liposomes; LPF: targeted Dox liposomes
LP LPD LPF
Particle size (nm) 115.1 ± 1.80 116.7 ± 1.10 121.5 ± 0.80
PDI 0.097 ± 0.020 0.052 ± 0.013 0.082 ± 0.023
Zeta potential (mV) − 27.6 ± 3.48 − 23.5 ± 1.87 − 23.9 ± 0.72
Fig. 1 Dox release profile of Dox liposomes and Dox 
immunoliposomes in FBS. Each point represents mean ± SD of three 
different batches analysed in duplicate. No statistical differences 
were found. Dox: Doxorubicin; LPD: conventional Dox liposomes; LPF: 
targeted Dox liposomes; FBS: fetal bovine serum
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EE (%), PDI or surface charge did not change (data not 
shown).
Immunoliposomes enhanced cellular uptake and cytotoxic 
effect
Cell uptake for targeted and non-targeted liposomes 
encapsulating Dox is represented in Fig.  2 (panel a). 
The intracellular mean fluorescent signal (MIF) meas-
ured after 4 h exposure was statistically higher for tar-
geted than for non-targeted liposomes, confirming 
the selectivity of the ligand by the PD-L1 expressed in 
B16OVA cells. This finding, corroborated by confocal 
microscopy in Fig.  2c, shows that although both for-
mulations reach the cytoplasm, the targeting provided 
higher signal intensity. However, the non-differences 
found after 24  h of continuous exposure suggest that 
the impact of the targeting is particularly relevant at 
short exposure times, whereas for longer times, non-
targeted liposomes might achieve an equilibrium across 
the membrane. The free drug, with rapid access to the 
nucleus, was used to illustrate the positive control 
(Fig. 2b).
Fig. 2 Doxorubicin fluorescent signal in B16OVA cells exposed to liposomes. a Fluorescent signal measured by flow cytometry after 4 and 24 h 
incubation with LPD and LPF. Bars represent the mean ± SD of three independent studies. b Confocal microscopy images of positive (free Dox 
treatment) and negative (untreated) controls; c Cellular images after 4 h exposure to LPD and LPF. The fluorescent signals: red for Dox and green for 
the nuclei. Dox: doxorubicin; LPD: conventional Dox liposomes; LPF: targeted Dox liposomes; MIF: mean intensity fluorescence signal
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Immunoliposomes induced higher cytotoxicity
Cytotoxicity exerted by Dox, both free and encapsu-
lated, after 4 h of exposure was assayed 72 h later. Fig-
ure  3b summarizes the  IC50 values, observing that the 
free drug, or positive control, displayed the highest 
cytotoxic activity, followed by the targeted liposomes 
with 30 times higher potency than LPD. This low activ-
ity of LPD is probably associated with the unspecific 
cell uptake (Fig. 2a) and the slow drug release rate.
Interestingly, the free Dox and LPF displayed similar 
cell viability profiles at low concentrations (< 1  µM), 
suggesting that the receptor binding, internalization 
and Dox release from the formulation rendered a drug 
bioavailability similar to the free drug (Fig. 3a).
Immunoliposomes were cleared faster than non‑targeted 
liposomes
Time profiles of Dox plasma concentrations measured 
in melanoma-bearing mice treated with free and encap-
sulated drug are represented in Fig. 4. Dox was quanti-
fied by HPLC (Additional file 1: Figure S1).
Table  2 lists the pharmacokinetic parameters cal-
culated by non-compartmental analysis. Differences 
in the  t1/2 between non-targeted (21  h), and targeted 
liposomes, (11  h) were also reflected in the drug 
exposure expressed as AUC 0-∞. In line with these dif-
ferences, total plasma clearance was approximately 
15 times higher for LPF compared to conventional 
pegylated liposomes. In contrast, free Dox, widely dis-
tributed and rapidly eliminated, achieved the lowest 
exposure.
Fig. 3 Cytotoxic activity of free and encapsulated Dox at 72 h after a 4 h exposure to treatments. a Survival curves (or cell viability curves) of 
B16OVA cells exposed to increasing Dox concentrations; b  IC50 concentration values. Data represent the average ± SD of three independent studies. 
Dox: doxorubicin; LPD: conventional Dox liposomes; LPF: targeted Dox liposomes;  IC50: Dox concentration able to inhibit 50% of cell proliferation 
compared to control
Fig. 4 Pharmacokinetics evaluation. The average of plasma 
concentrations (n = 3 mice) per time point is represented by symbols 
together with the mean standard deviation. Lines correspond to the 
interpolation data. Data were collected from B16OVA tumor bearing 
mice treated with a single intravenous dose (3 mg/kg) of free Dox, 
Conventional Dox liposomes (LDP) and Targeted Dox liposomes or 
immunoliposomes (LPF)
Table 2 Dox pharmacokinetic parameters calculated by a non-
compartmental analysis after 3 mg/kg dose of free Dox, LPD and 
LPF intravenously administered to tumor bearing mice
t1/2: Elimination half life; AUC: area under the curve of Dox plasma 
concentrations vs. time; Cl: total plasma clearance; Vd: volume of distribution; 
LPD: conventional Dox liposomes; LPF: targeted Dox liposomes; Dox: 
doxorubicin
t1/2 (h) AUC 0-∞ (µg h/mL) Cl (mL/h) Vd (mL)
Free Dox 6.99 0.60 99.6 1005.47
LPD 21.83 586.58 0.1 3.15
LPF 11.31 37.96 1.6 25.88
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Immunoliposomes triggered local and systemic antitumor 
immune response
The immune response exerted by the different formula-
tions was characterized in B16OVA tumor-bearing mice 
injected with a single dose, 3  mg/kg, of free Dox, LPD, 
LPD/free α-PD-L1 (28 µg/mouse) and LPF.
In tumor,  CD8+ T cell levels were not statistically dif-
ferent across treatments (Fig.  5a); however, targeted 
liposomes promoted a significant increment of specific 
and active tumor infiltrating T cells (TILs) (Fig.  5b–d). 
Indeed, in a deeper analysis of these TILs, mice treated 
with LPF presented a significant (p < 0.01) increase in 
tumor specific T cells  (Tetramer+/CD8+) and activated 
tumor specific lymphocytes  (PD1+Tetramer+/CD8+), 
reflecting a specific antigen response at the local tar-
get. This response was not induced by other treatments, 
including the combination of non-targeted liposomes 
and free α-PD-L1.
Interestingly, this immune status in tumor was in line 
with the systemic immune response analyzed in the 
spleen and lymph nodes, which was also higher after 
immunoliposomes administration (Fig.  6a). Note that 
Fig. 5 Immune response promoted by different treatments in tumor tissue. B16OVA tumor bearing mice were administered with different 
treatments: saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 (mAb) or Targeted Dox liposome 
or immunoliposomes (LPF). Dox was intravenously injected at 3 mg/kg and eight days later, tumors were removed to evaluate different T cell 
subpopulations. a  CD8+ cells; b Tumor specific cytotoxic T lymphocytes  (Tetramer+/CD8+); c Activated cytotoxic T lymphocytes  (PD1+/CD8+); d 
Activated  CD8+ tumor specific lymphocytes. Bars show the minimum and maximum value with the mean of each treatment. Data correspond to 
two independent assays. n = 8 in total **p < 0.01 compared to control group
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in the spleen, after the SIINFEKL pulse, LPF induced a 
strong  CD8+ activation; whereas in the lymph nodes, an 
increase in Granzyme B expression in  CD8+ cells was 
found, as is represented in Fig.  6b. Therefore, immu-
noliposomes exerted a systemic efficient activation of 
immune response, strengthening the tumor response, 
whereas this effect was not outperformed either by the 
chemotherapy or non-targeted liposomes alone or by the 
combination of LPD and free α-PD-L1.
Immunoliposomes were able to efficiently control 
the tumor growth
B16OVA melanoma-bearing mice were treated with 
3 mg/kg of Dox, free and encapsulated on LPD, LPF and 
LPD/α-PD-L1 (28 µg/mouse), every 72 h during 3 cycles.
All treatments provided an antitumor effect compared 
to the control group, as depicted in Fig.  7. However, 
encapsulated Dox was associated with more effective 
tumor shrinkage than with the free form. In addition, 
non-targeted liposomes in monotherapy or combined 
with free α-PD-L1 behave similarly, demonstrating 
that the 28  μg/mouse dose of the free antibody did not 
contribute significantly to the drug effect. In contrast, 
immunoliposomes achieved an efficient control of tumor 
growth for more than 40 days, as is observed in Fig. 7.
In fact, the Kaplan-Meyer curve shows that the over-
all survival for this group was 70 days, which represents 
a statistically significant (p < 0.0001) increase in the life-
span of almost 1 month compared with the non-targeted 
formulation. Indeed, the efficacy of LPD and Dox was 
similar (Fig. 8). No significant side effects such as loss of 
body weight or ulceration were found during the experi-
ments (Additional file 1: Figure S2).
Finally, the impact of the therapies on the antitumor 
effect was evaluated applying the RECIST (Response 
Evaluation Criteria In Solid Tumors) criteria [31, 32]. 
Figure 9 summarizes tumor growth dynamics over time, 
showing that at the end of treatments (day 17), all treated 
groups achieved a stable disease in a small percentage 
of mice, but the effect was transient. However, LPF was 
the only treatment that attained total tumor regression 
in 20% mice at day 27, a percentage that remained sta-
ble until the end of the experiment (day 69). In addition, 
50% of mice treated with LPF presented stable disease at 
day 27, suggesting that a new cycle of treatment might be 
beneficial.
Discussion
Currently, immunotherapy, in particular ICIs, has 
become a solid pillar for cancer treatment. Clinical ben-
efits such as total and long-term tumor remission in a 
minority of patients, have led investigators to use differ-
ent therapeutic combinations to increase that number 
of patients [14, 33]. In this context, Dox based-combina-
tions with different immune-approaches have been previ-
ously reported by several authors as a promising strategy 
[34–38]. Accordingly, the main objective of the present 
study was to develop and evaluate a novel single and 
Fig. 6 Systemic immune response was measured in spleen and lymph nodes collected from B16OVA tumor bearing mice treated with saline, free 
Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 (mAb) or Targeted Dox liposome or immunoliposomes 
(LPF). Dox was intravenously injected at 3 mg/kg and eight days later, organs were removed to analyze different T cell subpopulations. a 
Lymphocyte activation status determination in spleen after incubation with SIINFEKL peptides (ELISPOT); b Degree of activation (Granzyme B) 
measured in  CD8+ cells in lymph nodes after 4 h of stimulation with PMA/Ionomicin. Bars show the maximum and minimum range of data with the 
mean. Data belong to two independent studies involving eight mice. **p < 0.01 compared to control
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versatile nano-liposome combining Dox and α-PD-L1. 
To address this, our group formulated a new PD-L1 tar-
geted nanoplatform to block selectively this immune 
checkpoint [30]. Nevertheless, in this work, we present 
a more advanced liposome encapsulating Dox to exploit 
Fig. 7 Profiles of tumor growth measured in B16OVA tumor bearing mice intravenously administered with three cycles (cycle/every 72 h) of 
different treatments: saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 or Targeted Dox liposome 
or immunoliposomes (LPF). Dox was intravenously administered at 3 mg/kg and tumor growth was measured twice a week. Lines represent the 
average and standard deviation of 6 mice per group of treatment and arrows the three administrations
Fig. 8 Survival curves for the different treatments assayed in 
B16OVA melanoma-bearing mice. B16OVA tumor bearing mice 
intravenously administered with three cycles (cycle/every 72 h) of 
different treatments: saline, free Dox, Conventional Dox liposomes 
(LPD), LPD co-administered with 28 µg of free α-PD-L1 or Targeted 
Dox liposome or immunoliposomes (LPF). Dox was intravenously 
administered at 3 mg/kg and tumor progression was measured twice 
per week. Immunoliposomes increased significantly the survival rate 
in comparison with the other treatments (***p < 0.001)
Fig. 9 RECIST criteria applied to the therapeutic assay of liposomes. 
B16OVA tumor bearing mice intravenously administered with three 
cycles (cycle/every 72 h) of different treatments: saline, free Dox, 
Conventional Dox liposomes (LPD), LPD co-administered with 28 µg 
of free α-PD-L1 or Targeted Dox liposome or immunoliposomes 
(LPF). Dox was intravenously administered at 3 mg/kg and tumor 
progression was measured twice per week. The values, expressed as 
percentage, were calculated comparing the tumor size at a specific 
time point with its initial size at day 7 after cell inoculation
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the advantages of that nanoplatform, demonstrating 
enhancement not only of the antitumor immune effect, 
but also efficacy.
Here, the optimization of the methodology previously 
reported by Merino et al. (2019) [30] led us to formulate 
highly reproducible liposomes in terms of encapsulation, 
particle size, PDI or stability, providing similar formula-
tions with independence of the targeting [38–41].
The impact of the selective targeting assayed in 
B16OVA cells, overexpressing PD-L1 (PD-L1+), has 
resulted in the reduction of the  IC50 of Dox compared to 
non-targeted liposomes. This PD-L1 selectivity yielded 
higher drug uptake and thereby, higher intracellular 
bioavailability, similar to the result reported for gastric 
cancer cells overexpressing PD-L1, exposed to nanopar-
ticles conjugated with α-PD-L1 [42]. There, the cellu-
lar uptake correlated with a more effective inhibition of 
PD-L1 expression [42], but non-in vivo data were further 
explored. However, the in  vivo study is crucial to know 
the therapeutic benefit and pharmacokinetics behaviour. 
In this work a significant change in drug exposure across 
targeted, non-targeted and free drug was found. Indeed, 
the free drug presenting the highest cytotoxicity in the 
in-vitro studies did not correlated with the highest effi-
cacy in in-vivo.
Although PK parameters calculated using Dox mean 
concentration values, did not provide information about 
inter-individual variability or associated bias, results are 
in line with the literature [38, 40, 41]. Thus, free Dox 
was widely distributed and rapidly eliminated, a charac-
teristic associated with limited efficacy, as is observed 
here (Fig.  7) and serious adverse effects, justifying drug 
encapsulation into liposomes [20, 43–45]. This strat-
egy provided long-circulating liposomes, reducing Dox 
elimination and therefore, increasing the drug exposure, 
which was much higher than for immunoliposomes. This 
different behaviour, commonly reported in the litera-
ture for targeted liposomes [38, 43], can be explained by 
the ligand selective binding, proved in vitro, which pro-
motes faster clearance in comparison with conventional 
pegylated liposomes [38, 43]. Furthermore, the pre-
sent targeted formulation might also bind to the PD-L1 
expressed in certain blood circulating factors such as 
exosomes, soluble PD-L1 or immune cells, thus contrib-
uting to the targeted liposomes elimination [46–48]. In 
this regard, our group performed an ex-vivo assay. Dif-
ferentiated myeloid cells collected from murine bone 
marrow, were incubated with fluorescent targeted and 
non-targeted liposomes at different amounts of lipids. 
Cell uptake was much higher for targeted liposomes, 
correlating with a dramatic reduction of PD-L1 expres-
sion (Figure S3). Altogether, these findings support the 
involvement of myeloid cells in the capture of targeted 
liposomes. In this way, Xiong et  al. [49] have reported 
that the PD-L1 targeting to myeloid cells associated with 
depleting agents might be a good strategy to induce func-
tional remodeling of macrophage compartment, enhanc-
ing the efficacy of α-PD-L1 treatment.
However, despite the PK differences, the amount of tar-
geted liposomes in the tumor was sufficient to induce a 
significant increase in activated tumor-specific cytotoxic 
T-cells (Fig.  5). Hence, targeted liposomes increased 
 PD1+ /CD8+ T cells in tumor microenvironment, indi-
cating that the PD-L1 blockage might reinvigorate anti-
tumor immune function, which would be facilitated by 
Dox cytotoxicity, increasing the antigen release. In this 
line, Gurung et  al. (2020) [50] found a reinvigoration of 
 CD8+ T-cell after nine cycles of treatment with specific 
PDL-1-binding peptides attached to Dox-liposomes 
in CT26 colon tumor model. This result supports our 
hypothesis about the contribution of Dox in the ICI 
activity in a synergistic manner or at least, in a potentia-
tion. In fact, the dose of Dox was the same for all treat-
ments. However, Dox was not able to induce the same 
response, in particular the free Dox, associated with the 
lower efficacy. Furthermore, LPD co-administered with 
α-PD-L1 at the dose corresponding to LPF (28 µg/mouse) 
did not render any immune response. Interestingly, 
28 µg/mouse is far from 100 or 200 µg/mouse, the gener-
ally used dose for α-PD-L1 efficacy [8] or empty PD-L1 
targeted liposomes [30]. Therefore, Dox contributed to 
immune response activation only after immunoliposome 
administration.
Besides, targeted liposomes enable an immune activa-
tion in the spleen and lymph nodes that would support 
the modulation observed in tumor. Thus, the increase in 
 CD8+ T cells expressing Granzyme B reflects a specific 
activation of tumor-infiltrating T cells [8], even when 
non-differences in  CD8+ T cell numbers were observed 
across treatments. Note that TILs activation, expansion 
and infiltration in the tumor involve a dynamic process, 
which must be taken into consideration when selecting 
times for tumor and organ collection (spleen or lymph 
node), in order to detect the highest difference in TIL 
levels [8, 51].
To our knowledge, this is the first immunoliposo-
mal formulation that demonstrates systemic and local 
enhancement of the antitumor immune response, corre-
lating with the efficacy. Importantly, a remarkable delay 
in tumor growth and tumor shrinkage was observed 
after immunoliposomes administration, although full 
tumor regression was only observed in 20% of mice, simi-
lar to the previous observed for empty PD-L1 targeted 
liposomes but at a dose four times higher (100 µg/mouse) 
[30]. In addition, in this work the survival rate as well as 
the life span increased significantly, the latter by 1 month, 
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suggesting that another cycle of treatment might main-
tain the control of tumor progression or even increase the 
number of cured mice. Note that although all treatments 
were able to trigger an initial partial response at the end 
of treatments, it seemed insufficient to overcome the 
tumor growth. Hence, only LPF were able to achieve an 
antitumor immune activation able to control the tumor 
growth in a very aggressive melanoma mice model.
Conclusion
The PD-L1 targeted Dox liposomal formulation here 
developed and assayed in a melanoma murine model, has 
demonstrated an enhanced contribution of both compo-
nents, α-PD-L1 and Dox, in the control of tumor growth 
and elimination, enabling host antitumor immune modu-
lation. To date this is the first successful chemo-immuno-
therapeutic approach combined in an immunoliposome.
Furthermore, this formulation represents a versatile 
nano-platform for the encapsulation of different thera-
peutic molecules or co-encapsulation with fluorescent 
probes for theragnostic application not only in cancer, 
but even, in other illnesses.
Materials and methods
Materials
The lipids Hydrogenated Soy l-α-phosphatidylcholine 
(HSPC), Cholesterol (CH), 1,2-Distearoyl-sn-Glycero-
3-Phosphoethanolamine-N-[Methoxy(Polyethylene 
Glycol)-2000] (DSPE-PEG2000) and 1,2-Dis-
t e a r o y l - s n - G l y c e r o - 3 - P h o s p h o e t h a n o l a m i n e -
N-[Maleimide(Polyethylene Glycol2000)] 
(DSPE-PEG2000-Mal) were purchased from Avanti 
polar lipids Inc. (Alabama, USA). PD-10 desalting 
prepacked columns containing Sephadex G-25 resin 
were purchased from GE Healthcare Life Sciences 
(Pittsburgh,USA). Chloroform, Methanol, Trypsin–
EDTA, β-mercaptoethanol, Hepes, Sodium Chloride, 
β-Mercapto ethylamine hydrochloride (MEA), EDTA, 
Hepes, phorbolmyristate acetate(PMA), Ionomycin, 
Daunorubicin and Triton X-100 were purchased from 
Sigma Aldrich (Madrid, Spain). Dox was purchased 
from the Pharmacy Service (Clínica Universidad de 
Navarra, Pamplona, Spain). The cell culture medium 
Roswell Park Memorial Institute medium (RPMI-Glu-
tamax), Penicillin–Streptomycin (P/S) and Fetal Bovine 
Serum (FBS) were obtained from GIBCO (Madrid, 
Spain). α-PD-L1 (Clone 10F.9G2) was obtained from 
BioXCell (West Lebanon, USA). Collagenase and 
DNAse were purchased from Roche® (Basel, Switzer-
land) and ACK lysis buffer was obtained from Invitro-
gen (California, USA). Tris (2-carboxyethyl) phosphine 
(TCEP) and immobilized pepsin were obtained from 
Thermofisher (Massachusetts,USA). Centrifugal Filter 
Units (Amicons) of 10,000 and 30,000 MWCO were 
obtained from Merck (Darmstadt, Germany). The 
Recombinant Mouse B7-H1/Fc chimera was obtained 
from R&D Systems (Minnesota, USA). iTAgTM MHC 
Class I Murine Tetramer-SA-PE was obtained from 
Immudex (Copenhagen, Denmark) and (FITC)-con-
jugated α-mouse CD8α, Zombie-APCCy7 and APC 
α-mouse CD279 (PD-1) were purchased from BioLe-
gend (California, USA). GolgiStop™ and GolgiPlug™ 
were obtained from BD Biosciences (California, USA).
Methods
Targeted liposome preparation
Development of  Dox liposomes Liposomes were pre-
pared by the film-hydration method combined with a pH 
gradient for active drug loading [30, 38, 52].
Briefly, HSPC:CH:DSPE-PEG2000 at a molar 
ratio of 1.85:1:0.12, were dissolved in a solution of 
chloroform:methanol [9:1 (v/v)]. Organic solvents were 
removed by rotary evaporation (Büchi Waterbath B-480, 
Switzerland) at 65  °C obtaining the film, which was 
hydrated with ammonium sulphate (250  mM) at pH 
5.5 under constant stirring. The liposomal solution was 
extruded five times through a polycarbonate membrane 
with a drain disk. To obtain a homogeneous population 
of liposomes, membranes with different pore size were 
used, 200 nm, 100 nm and 80 nm.
Ammonium sulphate buffer was exchanged with Hepes 
saline buffer (Hepes 10  mM, EDTA 5  mM and NaCl 
150 mM; pH 6.7) through a PD-10 column and LPs were 
incubated with Dox at a molar ratio of 0.1:1(Dox:Lipid) 
in a thermoshaker (Vortemp 56, Labnet, USA) for 1 h at 
60 °C. Non-encapsulated Dox was removed by ultracen-
trifugation at 40,000 rpm for 2 h at 4 °C and the final Dox 
liposomal formulation was kept in Hepes saline at 4  °C 
until use.
α‑PD‑L1 Fab’ fragments The α-PD-L1 monovalent vari-
able fragment (Fab’) was obtained according to the meth-
odology reported by Merino et  al. [30]. Briefly, in the 
first step, α-PD-L1 was digested with in mobilized pep-
sin at 37 °C for 3 h in sodium acetate. This solution was 
washed with Hepes saline buffer using the Amicon system 
(MWCO 30  K) to collect F(ab’)2 fragments, which were 
incubated at 37  °C for 2 h with MEA solution (15 mM) 
and filtered (Amicon system, MWCO 10  K) to expose 
out sulfhydryl groups. These fragments were able to react 
with DSPE-PEG2000-Mal to form thioether bonds. To pre-
vent the disulfide crosslink in the fragments, these were 
treated for 1 h at 37 °C with TCEP (500 mM). The mixture 
was washed again, collecting the Fab’ fragments at 4  °C 
that were used within the next 4 h.
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Preparation of Dox immunoliposomes
The post insertion method [53, 54], based on the prepa-
ration of specific targeted micelles, was used to formu-
late α-PD-L1-Fab’ Dox liposomes. Micelles, composed 
of DSPE-PEG2000-Mal, were prepared at pH 6.7 in Hepes 
saline buffer and incubated overnight (ON) at 4  °C with 
Fab’ fragments, at a molar ratio of 750:1 (lipid:ligand) 
under constant stirring. Targeted micelles and preformed 
LPD were incubated together for 1 h at 60 °C, as is shown 
in Fig.  10. Formulated immunoliposomes were incu-
bated with 1 mM of l-cysteine to quench free maleimide 
groups. In order to prevent possible Dox release during 
this procedure, targeted liposomes were ultracentrifuged 
at 28,000  rpm, 4  °C for 3  h and resuspended in Hepes 
saline at 4 °C until use.
Characterization of liposomes
Physicochemical characterization
The different Dox formulations were characterized in 
terms of particle size, polydispersity index (PDI) and Zeta 
potential by laser diffractometry using a Zetasizer Nano 
Series system (Malvern Instruments, UK).
The encapsulation efficiency of Dox was measured by 
spectrophotometry (λ 485  nm), and loading efficiency 
was calculated by the following formula:
where, EE represents the percentage of drug entrap-
ment efficiency; Fa, the amount of drug encapsulated 
in liposomes divided by the final amount of lipids and 
Ia, the initial amount of the drug divided by the initial 
amount of lipids.
The lipid concentration in each batch was measured by 
the phosphate assay [55], whereas the ligand conjugation 
efficiency, was quantified using the Coomassie Protein 
assay reagent (Bio-Rad, California, USA). The number 
of attached ligand molecules was calculated according 
to the amount of protein and lipid, using the Avogadro’s 





over 3 months, characterizing particle size, PDI and Dox 
encapsulation at certain time points.
Non‑targeted and targeted liposomes stability
Dox release was measured by fluorimetry (λex 485  nm 
and λem 595  nm) using aliquots of 5  mM lipids (LPD y 
LPF) placed in 100% FBS and incubated at 37 °C. The Dox 
signal was recorded every second for 1 h. Afterwards, ali-
quots were treated with TritonX-100 (1%) to measure the 
encapsulated Dox. The accumulative release curves were 
built using the following formula:
where, Qa represents the amount of drug measured in 
the collected samples, and Qt, the total encapsulated 
amount. This experiment was evaluated in duplicate in 
three independent formulations.
In vitro studies
B16OVA murine melanoma cell line was kindly provided 
by Dr. Sandra Hervás-Stubbs (CIMA, Pamplona, Spain). 
The cell line is derived from B16-F10 and transfected 
with chicken ovalbumin, a protein that acts as a surrogate 
tumor antigen in the presence of Geneticin (50 mg/mL, 
Lonza®, Spain). B16OVA cells over-expressing PD-L1 
[30] were maintained in a mixture of RPMI-Glutamax 
cell culture medium, 10% FBS, 1% P/S, 2% Hepes and 
50 mM of β-mercaptoethanol under standard conditions. 
The presence of Mycoplasma was regularly tested (Lonza, 
Spain).
Cellular interaction of targeted and non‑targeted 
liposomes
B16OVA cells were seeded at a density of 8 ×  104 cells/
well in 12-well plates. Twenty-four hours later cells were 
exposed to 5 µg/mL of Dox encapsulated in LPD or LPF 
for 4 and 24  h at 37  °C. Afterwards, cells were washed 
and detached in 200 µL PBS. Dox-specific fluorescence 







Fig. 10 Schematic representation of the different steps used for Targeted Doxorubicin liposomes formulation
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(BD biosciences) and analyzed using FlowJo software v 
7.6.1 (TreeStar, USA).
Additionally, images were also captured by confocal 
microscopy. Cells were seeded in culture slides chambers 
(BD Falcon, Bedford, USA) at a density of 3 ×  104 cells/
well and treated with 5  µg/mL of Dox according to the 
protocol described above. After treatments, cells were 
washed several times and the nuclei stained in green with 
Hoechst (1:1000 in PBS) during 10 min at 37 °C. Images 
were acquired at 40× of magnification using the Axio 
Cam MR3 video camera connected to the Zeiss Imager 
M1 microscope (Carl Zeiss AG, Oberkochen, Germany) 
equipped with epifluorescence optics and Axiovison soft-
ware (4.6.3.0 version).
Cytotoxicity evaluation in PD‑L1+ cells
B16OVA cells were seeded in 96 wells plates (flat bottom) 
at a density of 5 ×  103 cells/well. Twenty-four hours later, 
cells were exposed for 4 h to different Dox concentrations 
(from 0.001 to 100  µM), free and encapsulated in LPD 
or LPF. Wells, washed three times with PBS, were incu-
bated at 37 °C in fresh medium for 72 h. Cytotoxicity was 
tested using the sulphorodamine B assay [57] and data, 
expressed as  IC50 (Dox concentration able to inhibit the 
50% of cell proliferation in comparison to control or non-
treated cells) were determined by a non-linear regression 
plotting cell survival vs. log concentration (GraphPad 
Prism software v 6.01).
In vivo evaluation of liposomal formulations
Female C57BL/6 mice (20  g or 5  weeks, supplied by 
Harlan, Barcelona, Spain) were housed in plastic cages 
under standard and sterile conditions (25 °C, 50% relative 
humidity, 12 h dark/light) with water and food ad libitum. 
All experiments were performed according to European 
animal care regulations, ARRIVE guidelines and the pro-
tocol approved by the Ethics Committee of the Univer-
sity of Navarra (Ref. 046-14). Mice were subcutaneously 
injected in the right flank with B16OVA melanoma cells 
in 100 μl of PBS (5 ×  105 cells/mouse). Tumor growth and 
body weight were monitored twice a week. When tumor 
size reached approximately a mean diameter of 5–6 mm, 
mice were randomly divided into several groups to assay 
different experiments (Fig. 11).
Pharmacokinetics behaviour of the different 
Dox‑formulations
C57BL/6J female mice (n = 27) inoculated with B16OVA 
cells were divided into three groups: free Dox, LPD 
and LPF, receiving a single intravenously dose of Dox, 
3  mg/kg. Blood samples were collected in EDTA tubes 
(SARSTEDT, Germany) via the maxillofacial vein at dif-
ferent time points post-injection, from 5  min to 168  h. 
Plasma was obtained by blood centrifugation at 3500 rpm 
for 15 min and used for Dox quantification by HPLC. The 
analytical system (HP 1100 Series Agilent) was equipped 
with a fluorescence detector (G1321A FLD) and Agilent 
ChemStation software (Germany). The chromatographic 
separation was performed with a Gemini®  C18 110 Å col-
umn (150 × 3  mm, particle size 5  µm, Phenomenex®). 
The mobile phase consisted of water (pH 2.5, acidified 
with orthophosphoric acid)/acetonitrile and the flow 
rate was 0.7 mL/min under gradient conditions, starting 
at 80/20 to change at 70/30 during the next 3 min, 0/100 
in the next 9  min and achieving the initial condition at 
10 min. The detection was performed at λem 480 nm and 
λex 558 nm. Calibration curves were prepared in 100 µL 
of murine plasma (Plasma Balb/C, GeneTex, Irvine, USA) 
using a stock solution of Dox and the internal standard, 
Daunorubicin (15  µg/mL). The linear range was from 
0.0125 to 1.5 µg/mL.
Time profiles of Dox plasma concentration admin-
istered under different formulations were built using 
the average value corresponding to the three mice used 
at each time point. The area under the plasma concen-
tration versus time curve (AUC 0-∞) was calculated by 
the linear trapezoidal method. For the extrapolated 
area, AUC last_obs-∞, the last concentration  (Clast_obs) was 
divided by the slope (k) obtained from the terminal por-
tion of the curve using data log-transformed:
Other parameters such as elimination half-life 
 (t1/2), plasma clearance (CL) and volume of distribu-
tion (Vd) were estimated according to the equations: 
[AUC]∞last_obs = Clast_obs/k
Fig. 11 Schematic representation of the three in-vivo studies 
performed in this work
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t1/2 = 0.693/k , CL = Dose/AUC0−∞ and Vd = CL/k , 
respectively.
Characterization of the immunological effect induced 
by liposomal formulations
The immune system activation provided by the differ-
ent formulations was studied in B16OVA tumor-bear-
ing mice. Briefly, when tumors reached the optimal size, 
mice were randomly divided into different groups: Con-
trol, free Dox, LPD, LPD plus free α-PD-L1 (1.2 mg/kg) 
and LPF. Treatments consisted of a single i.v. dose of 
3  mg/kg of Dox. One week later, mice were sacrificed 
and tumors, spleens and lymph nodes were collected 
for further analysis.
Tumor tissues were digested with 5  mL collagenase/
DNase (10:1) at 37 °C for 30 min, neutralized with 50 µL 
of EDTA and centrifuged for 2 min at 1800 rpm. Pellets 
were lysed with 1 mL of ACK lysis buffer (Lonza, USA), 
neutralized with PBS and transferred to 96 well microti-
ter plates for staining.
After 10  min incubation at room temperature with 
Zombie-APC-Cy7 (1:1000 v/v in PBS), cells were again 
incubated 10  min at 4  °C with FC blocking antibody 
(1:200, v/v) in Facs buffer (5% FBS and 0.5% EDTA 
in PBS) to reduce unspecific bindings. Samples were 
incubated with iTAgTM MHC Class I Murine Tetramer-
SA-PE (1:50) for 30  min at 4  °C, washed and treated 
for 15 min at 4  °C with a mixture of (FITC)-conjugated 
α-mouse CD8α (1:200) and APC α-mouse CD279 (PD-
1) (1:200). Cells were washed and resuspended in Facs 
buffer at 4 °C until flow cytometry analysis.
Spleen samples were analyzed by the Elispot assay. The 
day before the experiment, a 96 well Elispot microtiter 
plate was coated with the capture antibody overnight 
(1:200 dilution in PBS) at 4  °C. Twenty-four hours later, 
the plate was washed and blocked for 2 h by adding com-
plete RPMI culture medium. Samples were processed 
in the lysis buffer for 2 min, neutralized with RPMI cul-
ture medium and centrifuged at 1800 rpm for 2 min. The 
pellets, resuspended in complete RPMI medium, were 
incubated overnight at a density of 1 ×  106 cells/well 
with SIINFEKL peptide (1 µg/mL) or ovalbumin protein 
(10 µg/mL) at 37  °C. Twenty four hours later, cells were 
washed and incubated for 2  h with the detection bioti-
nylated antibody (1:250) prepared in PBS and 10% FBS. 
These cells were incubated for 1 h with Streptavidin-HRP 
(1:100) and treated in darkness with a substrate solution 
(AEC substrate set, BD) until the spots emerged. The 
reaction was stopped by adding water and the spots were 
counted with the ImmunoSpot program.
Fig. 12 Schematic representation of the dose schedule applied to evaluate the antitumor response in the in-vivo study
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Lymph nodes were mashed in PBS and stimulated for 
5  h with PMA (50  µg/mL) and Ionomycin (1  µg/mL). 
For intracellular staining, cells were incubated with BD 
GolgiStop™ and GolgiPlug™ (BD, 1:1000 dilutions), 
stained with PE labelled H-2 kb/OVA257-264-tetramers 
(MBL) and also with fluorochrome-conjugated antibod-
ies against CD8, NKp46 and CD44, in the presence of 
purified α-CD16/32. In the next step, cells were fixed and 
permeabilized with the BD Fixation/Perm buffer (BD) to 
stain with granzyme B (GB11) antibody. Samples were 
acquired on a FACS Canto-II cytometer (BD Biosciences) 
and data were analyzed using FlowJo software (TreeStar). 
Cell death was detected with Zombie NIR Fixable dye 
(1:1000).
Antitumor efficacy study
Antitumor efficacy was studied in C57BL/6  J tumor-
bearing mice (n = 60) randomly grouped into control, 
free Dox, LPD, LPD/α-PD-L1 and LPF (Fig.  12). Treat-
ments consisted of 3  mg/kg Dox administered intrave-
nously every 72  h, for three doses, and for α-PD-L1, in 
the combination, was 28  µg/mouse, the dose equivalent 
to the conjugated to LPF. Mice body weight and other 
side effects were measured over time until the end of the 
experiment. Tumor size was calculated by the following 
formula:
where, a represents the shortest and b, the largest dimen-
sions of the tumor.
Statistical analysis
The statistical analysis was performed using GraphPad 
Prism 5 software (version 6.01) (GraphPad Software, 
San Diego, USA). The one-way ANOVA test was used 
to compare all groups together, followed by the Bonfer-
roni’s test for checking the differences between groups. 
Statistical analysis of survival data was performed in 
RStudio (version 3.6.3) using the Survfit function from 
the survival package that computes the Kaplan–Meier 
estimator for truncated and/or censored data. The log-
rank test was used to compare the different treatment 
groups. Statistical significance was set at 0.05.
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